RecruitingPhase 3NCT06686771
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Canadian Cancer Trials Group
- Principal Investigator
- C. Jillian TsaiUniversity Health Network Princess Margaret Hospital, Toronto, ON Canada
- Intervention
- SBRT(radiation)
- Enrollment
- 320 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (30)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- City of Hope at Irvine Lennar, Irvine, California, United States
- Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States
- Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States
- Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States
- Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States
- Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States
- Alton Memorial Hospital, Alton, Illinois, United States
- Northwestern University, Chicago, Illinois, United States
- Decatur Memorial Hospital, Decatur, Illinois, United States
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois, United States
- Crossroads Cancer Center, Effingham, Illinois, United States
- Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States
- Northwestern Medicine Glenview Outpatient Center, Glenview, Illinois, United States
- Northwestern Medicine Grayslake Outpatient Center, Grayslake, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Alliance for Clinical Trials in Oncology · ECOG-ACRIN Cancer Research Group · NRG Oncology · SWOG Cancer Research Network
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06686771 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07224152NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987956Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- RECRUITINGPHASE2NCT07104630Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGEARLY PHASE1NCT07274813A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsShanghai Henlius Biotech
- RECRUITINGPHASE1NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsOscotec Inc.
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
- RECRUITINGPHASE2NCT06656598Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung CancerIntergroupe Francophone de Cancerologie Thoracique
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →